

China Biologic Products, Inc.
Form 4
May 23, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Yin Ming

(Last) (First) (Middle)

18TH FLOOR, JIALONG
INTERNATIONAL, BUILDING, 19
CHAOYANG PARK ROAD

(Street)

BEIJING, F4 100125

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
China Biologic Products, Inc.
[CBPO]

3. Date of Earliest Transaction
(Month/Day/Year)
05/16/2016

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)
Senior Corporate VP

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/16/2016		M ⁽¹⁾	V Amount (1) 30,000 (A) or (D) A \$ 12.26	51,419	D	
Common Stock	05/19/2016		S ⁽¹⁾	(1) 10,973 (A) or (D) D \$ 113.83	40,446	D	
Common Stock	05/20/2016		S ⁽¹⁾	(1) 8,645 (A) or (D) D \$ 113.4	31,801	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (right to buy) ⁽⁴⁾	\$ 12.26	05/16/2016		M	30,000	10/11/2010 07/11/2020	Common Stock 30,000
Stock Option (right to buy) ⁽⁵⁾	\$ 9.85	05/16/2016		M	7,952	09/01/2013 08/31/2022	Common Stock 7,952

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Yin Ming 18TH FLOOR, JIALONG INTERNATIONAL BUILDING, 19 CHAOYANG PARK ROAD BEIJING, F4 100125	Senior Corporate VP

Signatures

/s/ Yin Ming 05/23/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Represents 10,973 shares of common stock (the "May 19 Sold Common Stock") sold on the open market at a weighted average price of \$113.83 per share on May 19, 2016, and 8,645 shares of common stock (the "May 20 Sold Common Stock," and together with the May 19 Sold Common Stock, the "Sold Stock") sold on the open market at a weighted average price of \$113.40 per share on May 20, 2016. The Sold Stock was acquired by the Reporting Person through the exercise of stock options to purchase 30,000 shares of the Issuer's

Edgar Filing: China Biologic Products, Inc. - Form 4

common stock. See Footnote 4 below for further details on the relevant stock options. The Reporting Person intends to use the proceeds from the sales of the Sold Stock to pay income tax due in connection with the Reporting Person's exercise of the stock options disclosed in Footnotes 4 and 5 to this Form 4.

- (2) The price reported in Column 4 is a weighted average price. The May 19 Sold Common Stock was sold in multiple transactions in the open market at prices ranging from \$113.50 to \$115.35, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4.
- (3) The price reported in Column 4 is a weighted average price. The May 20 Sold Common Stock was sold in multiple transactions in the open market at prices ranging from \$113.00 to \$114.00, inclusive.
- (4) Represents previously reported stock options to purchase 30,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated July 11, 2010. The options were scheduled to vest in 12 equal portions on a quarterly basis over a three-year period, with the initial vesting date being October 11, 2010, provided that the Reporting Person is employed by the Issuer on each vesting date.
- (5) Represents previously reported stock options to purchase 7,952 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated August 31, 2012. The options were scheduled to vest in four equal portions on a quarterly basis over a four-year period, with the initial vesting date being September 1, 2013, provided that the Reporting Person is employed by the Issuer on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.